# Panacea Biotec Limited (PANACEABIO)

> PANACEABIO closed at ₹311.10 on 30 Oct 2026, market cap ₹1,907 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Panacea Biotec Limited (NSE: PANACEABIO) closed at ₹311.10 on 30 Oct 2026, -30.3% over one year, against a 52-week range of ₹292.40 – ₹647.00.

In the quarter ended 30 Jun 2026 (consolidated, filed 13 Aug 2026) it reported revenue of ₹200 cr and net profit of ₹2 cr, a 1.2% net margin; revenue grew 19.7% and profit fell 45.6% year on year.

No trailing P/E is published: trailing twelve-month earnings are negative (-7 cr), so a P/E has no meaning — a loss-making business is not 'cheap' at a negative multiple. Judge it on revenue growth, cash burn and funding instead.

From the balance sheet dated 31 Mar 2026: return on equity 1.1%, ROCE 2.1%, debt-to-equity 0.03, Piotroski F-score 5 of 9.

Against 66 Healthcare peers on NSE: Net margin higher than 5% of 64 sector peers; PBT margin higher than 3% of 64 sector peers; ROE higher than 6% of 64 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹311.10 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -17.0% / -15.6% / -30.3% |
| 52-week low – high | ₹292.40 – ₹647.00 |
| Market capitalisation | ₹1,907 cr |
| Price / book | 2.28 |
| EV / EBITDA | 65.6 |
| TTM EPS | ₹-1.16 |
| TTM net profit | ₹-7 cr |
| Quarter revenue | ₹200 cr |
| Quarter net profit | ₹2 cr |
| Net margin | 1.2% |
| Revenue growth (YoY) | +19.7% |
| Profit growth (YoY) | -45.6% |
| Return on equity | 1.1% |
| ROCE | 2.1% |
| Debt / equity | 0.03 |
| Current ratio | 1.47 |
| Free cash flow | ₹-37 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹2.7 cr |

## Questions

### What were Panacea Biotec Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Panacea Biotec Limited reported revenue of ₹200 cr and net profit of ₹2 cr (consolidated), filed with the exchange on 13 Aug 2026.

### What is Panacea Biotec Limited's ROE?

Return on equity is 1.1% based on the balance sheet dated 31 Mar 2026.

### Does Panacea Biotec Limited have debt?

Debt-to-equity is 0.03 on the balance sheet dated 31 Mar 2026.

### What is PANACEABIO's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, PANACEABIO traded between ₹292.40 and ₹647.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/PANACEABIO

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._